11740 Results

People

  1. Vickers
    Vickers
  2. Offit
    Offit
  3. Robson
    Robson
  4. Horwitz
    Horwitz
  5. Kingham
    Kingham
  6. Panageas
    Panageas
  7. Breitbart
    Breitbart
  8. Halpern
    Halpern
  9. Jarnagin
    Jarnagin
  10. Nelson
    Nelson

Groups

  1. Population Sciences Research Program (11740)
  2. Survivorship Research (5670)
  3. Department of Medicine (5134)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3333)
  6. Surgery (2965)
  7. Psychiatry and Behavioral Sciences, Department of (2780)
  8. Biostatistics Service (2339)
  9. GSK Faculty (2008)
  10. Health Outcomes Research Group (1948)
  1. "Population Sciences Research Program"
Formats
  1. Journal Article (7144)
  2. Meeting Abstract (3306)
  3. Book Section (330)
  4. Review (289)
  5. Editorial (253)
  6. Research Letter (116)
  7. Correspondence (111)
  8. Conference Paper (67)
  9. Guidelines (59)
  10. Miscellaneous (41)
  11. Book Whole (24)
Groups
  1. Population Sciences Research Program (11740)
  2. Survivorship Research (5670)
  3. Department of Medicine (5134)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3333)
  6. Surgery (2965)

More Groups

People
  1. Andrew Vickers (880)
  2. Kenneth Offit (788)
  3. Mark Robson (676)
  4. Steven Horwitz (645)
  5. T Peter Kingham (609)
  6. Katherine Panageas (512)

More People

Years
  1. 2025 (235)
  2. 2024 (722)
  3. 2023 (821)
  4. 2022 (828)
  5. 2021 (786)
  6. 2020 (738)

More Years

Publications
  1. Journal of Clinical Oncology (1246)
  2. Blood (374)
  3. Psycho-Oncology (347)
  4. Cancer (240)
  5. Cancer Research (234)
  6. Annals of Surgical Oncology (233)

More Publications

Publishers
  1. American Society of Clinical Oncology (1412)
  2. Elsevier Inc. (1128)
  3. Springer (1112)
  4. Elsevier Science, Inc. (816)
  5. Oxford University Press (753)
  6. Wiley Blackwell (614)

More Publishers

Results (11740)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: Primary results of the phase 2 VALENTINE-PTCL01 study
    Meeting Abstract

    Horwitz, S. M.; Izutsu, K.; Mehta-Shah, N.; Cordoba, R.; Barta, S. K.; Bachy, E.; Gritti, G.; Jacobsen, E.; Kusumoto, S.; Guillermin, Y.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Valemetostat for relapsed or refractory peripheral T-cell lymphomas: Primary results from a phase 1 trial
    Meeting Abstract

    Jacobsen, E.; Maruyama, D.; Porcu, P.; Tobinai, K.; Allen, P. B.; Ishitsuka, K.; Tsukasaki, K.; Kusumoto, S.; Foss, F. M.; Yamauchi, N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Novel causal inference method estimates treatment effects of contemporary drugs in a global cohort of patients with relapsed and refractory mature T-cell and NK-cell neoplasms
    Meeting Abstract

    Koh, M. J.; Boussi, L.; Han, J. X.; Peng, L.; Sorial, M. N.; Eche-Ugwu, I. J.; Miranda, E.; Chiattone, C.; Stuver, R.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Genetic determinants of clonal hematopoiesis and progression to hematologic malignancies in 479,117 individuals
    Meeting Abstract

    Liu, J.; Tran, D.; Chan, I. C. C.; Wiley, B.; Watson, C.; Batchi-Bouyou, A. L.; Zong, X.; Stopsack, K. H.; Pharoah, P.; Ding, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Reduced dose brentuximab vedotin for mycosis fungoides appears to prolong response duration by balancing efficacy and tolerability
    Meeting Abstract

    Munayirji, B.; Khan, N.; Myskowski, P.; Geller, S.; Noor, S.; Kheterpal, M. K.; Davey, T.; Hancock, H.; Perez, L.; Miller, T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Quality of life and global response score in cutaneous T-cell lymphoma
    Meeting Abstract

    Khan, N.; Drill, E.; Moskowitz, A.; Shinohara, M. M.; Larocca, C.; Querfeld, C.; Zain, J. M.; Horwitz, S. M.
    Blood (2023)

    Fulltext@MSK | Save
  • DNA liquid biopsies for cancer-associated venous thromboembolism prediction
    Meeting Abstract

    Jee, J.; Brannon, A. R.; Fong, C.; Lee, A.; Gray, L.; Pichotta, K.; Luthra, A.; Diosdado, M.; Haque, M.; Guo, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • E7820, an anti-cancer sulfonamide, in combination with venetoclax in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial
    Meeting Abstract

    Bewersdorf, J. P.; Chandhok, N. S.; Watts, J. M.; Derkach, A.; Abdel-Wahab, O.; Stein, E. M.; Taylor, J.
    Blood (2023)

    Fulltext@MSK | Save
  • Carfilzomib,lenalidomide and dexamethasone (KRd) as induction therapy in high-risk newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Korde, N.; Derkach, A.; Hultcrantz, M.; Maclachlan, K. H.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of romiplostim on overall survival in chemotherapy induced thrombocytopenia
    Meeting Abstract

    Wilkins, C. R.; Zwicker, J. I.; Derkach, A.; Burge, M.
    Blood (2023)

    Fulltext@MSK | Save